Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

285 Stories from Volunteers, Donors & Supporters

1 John298

General Member of the Public

Rating: 5

In a country where the government prohibits legitimate scholarly research into the efficacies of natural plant medicines, MAPS bravely marches forward, providing valuable information to the people regarding plant medicine treatments that are otherwise suppressed. Eventually, in the face of overwhelming evidence, the government will have no choice but to allow the use of plant medicines. MAPS appears to be totally committed to amassing evidence and providing valuable information to the public until the tipping point is attained.

Rebecca129

General Member of the Public

Rating: 5

The work that MAPS does is not only revolutionary, but necessary. MAPS advocates for the use of medicines that have been outlawed for nothing other than political reasons; said medicines have beautiful transformational power and provide an alternative method for folks dealing with diseases from depression to addiction, to end-of-life anxiety. MAPS advocates for the necessity of the scientific community having access to these medicines so that society is able to empirically understand their potential. Without the ability to and benefits of research, we are left in the dark and must rely on anecdotal information that the government provides. With the amount of healing that is needed on American soil, these medicines MUST be studied. Politics must not prevail. Power to the people. Just say know. Thank you for all that you do, MAPS, you are changing lives across the globe!

General Member of the Public

Rating: 5

MAPS is saving lives ! They make the progress of getting to know our psyche to accelerate !

Drake B.

General Member of the Public

Rating: 5

MAPS is an inspiration and is saving lives. Period.
They are helping us understand the human psyche better and leading us to a future of greater mental health through connection with eachother, the planet and Source.

Dawn96

General Member of the Public

Rating: 5

My son suffers from PTSD and has tried many prescription drugs none have helped and many made it worse. He has only found relief with cannabis but in most places cannot get medical card for this condition and continues to suffer. I am thankful to MAPS for supporting research and use of these alternatives!

Mariusz J.

General Member of the Public

Rating: 5

I have suffered from PTSD and have coincidentally found out about MDMA being used to treat the symptoms, also found out about MAPS clinical studies and work to make marijuana and psychedelics a prsescription medicines. I am very thankful for their work, they've done a great job :) drugs that are prohibited work much better than pharmaceutical drugs, which makes me feel completely negative towards big pharma, they create customers, not cures. It's time for revolution !

Jason89

General Member of the Public

Rating: 5

After ten years of participating in AA to address what was a debilitating alcoholism I came to realize, as many scientists studying addiction pathology and treatment are now finding, that the 12 step model was not only horribly ineffective and unsuccessful- it actually hampered my recovery and personal growth. It was out of desperation that I saught out psychedelic therapy after researching addiction online for the better part of a year and I'm so incredibly thankful that I did as it not only ended my physical addiction it disabused me of the PTSD, toxic shame, and poisonous resentments that were the fuel for my discontent and compulsion to self-medicate with booze. I was relieved of my self centeredness and shown my roll in my own situation, I was blessed with a sense of increased empathy which allowed me to forgive those I was harboring resentments towards who had abused and neglected me as a child. This increased empathy was not temporary, and has continued to enrich my life two years later. I have also disabused myself of misleading neo con propaganda and denounced my previous stance as a militant atheist islamophobe I went from denouncing all of Islam to advocating for displaced and occupied Palestinians. Psychedelic therapy not only cured my addiction, it showed me addiction wasn't even disease- it was a symptom of a larger affliction I was unaware I even had- this condition was of a spiritual nature. Psychedelics didn't chemically cure me- they simply brought me into a spiritual place where I could heal myself. The power doesn't come from a chemical, it comes from us- I never knew I had this power within me. We all have this potential for healing, insight, growth of empathy, and MAPS is far and away at the forefront of the bringing psychedelic therapy research and the resulting conversation to the forefront, and this is why it is essential that we support them. Psychedelic therapy is absolutely thee future of addiction and trauma treatment and the future is happening... Now.

1

General Member of the Public

Rating: 5

I have volunteered and donated to various non-profits over my many years. Some 6 or so years ago I became aware of the work of MAPS and attended my first conference in 2013. Was I ever impressed! What an extraordinary group of people are involved. I am still feeling the "workshop high" I left with and no it isn't something I smoke or ingest! Presenters were passionate about their work and it was heartening to observe that. It is clear that the work MAPS is doing has far-reaching possibilities to help people with serious and intractable health issues. There is an urgency to their work and I want to see them flourish.

General Member of the Public

Rating: 5

MAPS has been an invaluable resource in navigating my own mental health and understanding how tools such as MDMA have helped those with PTSD and other anxiety disorders. The fear surrounding psychedelic medicines has resulted in disinformation and prohibition, thus making it impossible for those in need to access these potentially life-saving medicines. I have enormous respect for an organization like MAPS, who are bringing much needed sanity and research to this field. Few have been brave enough to take on such work, given the nature of the drug war, legal complexities, and lack of financial gain. And so I am very grateful for MAPS and their work and hope that funding for this vital research continues to grow.

General Member of the Public

Rating: 5

If we want to heal this world, first we have to heal ourselves. Psychedelic agents can be used as incredible tools of healing, but in the wrong hands, with the wrong attitude, they can be very dangerous as well. MAPS is the organization which took up the task of finding a suitable, safe context for the use of psychedelic medicines, one which could be seamlessly integrated into our modern Western society.

Neither the psychedelic be-ins of the sixties, nor the Goa parties of the 90s, nor the traditional ayahuasca rituals of Amazonian tribes could be integrated in such a way that they reached more than a few percent of the population. It would be very difficult for most people to get over the somewhat "fringe" nature of these contexts. But psychedelic psychotherapy - which grew out of well-established Western traditions of psychology and psychiatry - could be a game changer.